Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TUAN HUY V TRAN

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1750369161
CMS profile
352285
Location
METAIRIE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$6,145.14

147 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,835.63 141
Consulting Fee $2,250.00 1
Travel and Lodging $1,038.16 2
Education $21.35 3

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TUAN HUY V TRAN

NPI 1750369161 · CMS profile ID 352285

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

METAIRIE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750369161?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TUAN HUY V TRAN, NPI 1750369161, CMS profile ID 352285. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750369161?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). TUAN HUY V TRAN, NPI 1750369161, CMS profile ID 352285. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750369161?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
TUAN HUY V TRAN, NPI 1750369161, CMS profile ID 352285, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750369161?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

147 matching records · $6,145.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 147 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–147 of 147.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $2.9404/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695422469 CMS
SANOFI-AVENTIS U.S. LLC $17.1904/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694280985 CMS
Medtronic MiniMed, Inc. $13.3204/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648789931 CMS
AbbVie, Inc. $19.6504/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647862729 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.0303/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700084417 CMS
Novo Nordisk Inc $14.6403/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669481251 CMS
Abbott Laboratories $6.8603/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664395843 CMS
Merck Sharp & Dohme Corporation $13.0103/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695390335 CMS
Lilly USA, LLC $12.5003/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658203519 CMS
Dexcom, Inc. $112.2703/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527521 CMS
Merck Sharp & Dohme Corporation $12.0903/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695413401 CMS
Novo Nordisk Inc $18.0503/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669481249 CMS
Novo Nordisk Inc $14.0003/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669481253 CMS
SANOFI-AVENTIS U.S. LLC $4.6403/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693953653 CMS
AstraZeneca Pharmaceuticals LP $19.9502/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685375153 CMS
AstraZeneca Pharmaceuticals LP $46.0902/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685863761 CMS
AbbVie, Inc. $18.1202/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647862731 CMS
Corcept Therapeutics $2,250.0002/23/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695521387 CMS
Corcept Therapeutics $61.2002/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695521393 CMS
Corcept Therapeutics $5.6902/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695521403 CMS
Corcept Therapeutics $230.3602/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695521417 CMS
Corcept Therapeutics $976.9602/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695521425 CMS
Corcept Therapeutics $131.7402/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695521407 CMS
AstraZeneca Pharmaceuticals LP $22.4102/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685658519 CMS
AstraZeneca Pharmaceuticals LP $6.0002/21/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685865979 CMS
Insulet Corporation $15.3502/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705036961 CMS
Novo Nordisk Inc $13.0002/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668799759 CMS
Amarin Pharma Inc. $12.7802/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699080917 CMS
Merck Sharp & Dohme Corporation $13.5102/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695284909 CMS
Abbott Laboratories $19.2902/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664391615 CMS
Becton, Dickinson and Company $20.2402/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703302703 CMS
Merck Sharp & Dohme Corporation $15.5502/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695264513 CMS
Amgen Inc. $11.4002/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663142679 CMS
AstraZeneca Pharmaceuticals LP $119.0402/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685219083 CMS
Novo Nordisk Inc $21.6402/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668799831 CMS
Merck Sharp & Dohme Corporation $12.4901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695306463 CMS
SANOFI-AVENTIS U.S. LLC $7.0001/24/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693893039 CMS
Lilly USA, LLC $13.8201/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658207915 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.8701/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700084419 CMS
Merck Sharp & Dohme Corporation $15.3801/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695215433 CMS
AbbVie, Inc. $16.4001/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647862727 CMS
Dexcom, Inc. $14.7401/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527527 CMS
Novo Nordisk Inc $16.5101/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668799793 CMS
Novo Nordisk Inc $3.7501/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682912307 CMS
Lilly USA, LLC $13.7401/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658207913 CMS
AstraZeneca Pharmaceuticals LP $24.1501/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685104173 CMS
Dexcom, Inc. $10.9301/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527531 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,145.14 147
PY2020 $2,669.33 163
PY2021 $2,784.16 159
PY2022 $10,533.07 156
PY2023 $3,311.72 138
PY2024 $5,449.02 165
PY2025 $3,122.29 168

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $345,318.89 47
PY2024 Principal investigator $330,947.66 35
PY2023 Principal investigator $356,190.10 25
PY2022 Principal investigator $236,380.90 21
PY2021 Principal investigator $282,458.50 109
PY2020 Principal investigator $307,425.92 96
PY2019 Principal investigator $83,728.00 36

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH LLC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202535091
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,433.00 12/18/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225415052
Principal investigator 1 ABBVIE INC. $4,652.10 12/05/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529214
Principal investigator 1 ABBVIE INC. $8,935.65 11/05/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522997
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,730.00 10/23/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225414114
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,400.78 10/16/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312057
Principal investigator 1 ABBVIE INC. $12,282.30 10/09/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514839
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,000.00 09/24/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190307067
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,553.00 09/22/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190312059
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,178.00 09/18/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225414812
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,050.00 09/10/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185555125
Principal investigator 1 Novartis Pharmaceuticals Corporation $454.28 09/08/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190311387
Principal investigator 1 ABBVIE INC. $6,054.75 09/04/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508542
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,631.00 08/29/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225408556
Principal investigator 1 ABBVIE INC. $9,396.00 08/06/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503471
Principal investigator 1 ABBVIE INC. $383.09 07/10/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202497806
Principal investigator 1 ABBVIE INC. $8,726.40 07/02/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494411
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,376.29 06/30/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190307057
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,000.00 06/24/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190311385
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,239.00 06/19/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412422
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $19,593.00 06/05/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412382
Principal investigator 1 ABBVIE INC. $10,609.65 06/03/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488157
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,627.74 05/21/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190307063
Principal investigator 1 ABBVIE INC. $10,162.80 05/07/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483857
Principal investigator 1 Novartis Pharmaceuticals Corporation $794.50 05/01/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190307065
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $110.00 04/30/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225406640
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,849.00 04/28/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225403695
Principal investigator 1 Novartis Pharmaceuticals Corporation $280.61 04/23/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190307061
Principal investigator 1 ABBVIE INC. $3,896.10 04/03/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202472500
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,843.27 03/31/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190307055
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,299.00 03/27/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225403241
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $246.07 03/19/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225404529
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,440.00 03/19/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225405120
Principal investigator 1 ABBVIE INC. $1,393.20 03/07/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202460689
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,715.00 02/27/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190311373
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,926.17 02/27/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190311377
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,006.00 02/19/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225403931
Principal investigator 1 ABBVIE INC. $2,454.30 02/06/2025 Non-covered Recipient Entity
DBA OMEGA CLINICAL RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448387
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,650.52 02/04/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190311383
Principal investigator 1 Eli Lilly and Company $330.00 01/31/2025 Non-covered Recipient Entity
DIABETES AND METABOLISM ASSOCIATES, APMC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN ADULTS WITH CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187879945
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,707.61 01/28/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190311379
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,109.06 01/27/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190311375
Principal investigator 1 Eli Lilly and Company $23,683.00 01/21/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH LLC DBA TUAN HUY TRAN
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN ADULTS WITH CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187890516
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,531.80 01/17/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
a randomised,double blind,placebo controlled study to evaluate cortisol reserve in response to adrenocorticotropic hormone stimulation test following treatment with baxdrostat for eight weeks in participants with ucontrolled hypertension No dispute reported 06/30/2026 1185555123
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,434.00 01/17/2025 Non-covered Recipient Entity
Omega Clinical Research Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411824
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,717.71 01/15/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190307059
Principal investigator 1 Novartis Pharmaceuticals Corporation $913.14 01/08/2025 Non-covered Recipient Entity
OMEGA CLINICAL RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190311381